Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2013112438) STABILIZED FORMULATIONS CONTAINING ANTI-ANG2 ANTIBODIES
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2013/112438 International Application No.: PCT/US2013/022473
Publication Date: 01.08.2013 International Filing Date: 22.01.2013
IPC:
C07K 16/22 (2006.01) ,A61K 39/395 (2006.01) ,A61K 47/06 (2006.01) ,A61K 47/26 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
22
against growth factors
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
06
Organic compounds
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
06
Organic compounds
26
Carbohydrates
Applicants:
REGENERON PHARMACEUTICALS, INC. [US/US]; 777 Old Saw Mill River Road Tarrytown, New York 10591, US
Inventors:
WALSH, Scott; US
DIX, Daniel; US
Agent:
TERMES, Lance, A.; Alston & Bird LLP Bank of America Plaza Suite 4000 101 South Tryon Street Charlotte, NC 28280-4000, US
Priority Data:
61/589,42723.01.2012US
Title (EN) STABILIZED FORMULATIONS CONTAINING ANTI-ANG2 ANTIBODIES
(FR) FORMULATIONS STABILISÉES CONTENANT DES ANTICORPS ANTI-ANG2
Abstract:
(EN) The present disclosure provides pharmaceutical formulations comprising an antibody that specifically binds to angiopoietin 2 (Ang-2). The formulations may contain, in addition to an anti-Ang-2 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present disclosure exhibit a substantial degree of antibody stability after storage for several months and after being subjected to thermal and other physical stress.
(FR) La présente invention concerne des formulations pharmaceutiques comprenant un anticorps qui se lie spécifiquement à l'angiopoïétine 2 (Ang -2). Les formulations peuvent contenir outre un anticorps anti-Ang -2, un acide aminé au moins, un sucre au moins ou un agent tensioactif non ionique au moins. Les formulations pharmaceutiques de la présente invention présentent un degré sensible de la stabilité des anticorps après un stockage pendant plusieurs mois et après avoir été soumis à des contraintes thermiques et physiques.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)